Can sequencing chemotherapy and immunotherapy transform ALL treatment?
Hagop Kantarjian, MD, interviews Nicholas Short, MD, on treatment sequencing in precursor B-cell ALL and in the relapsed or refractory setting.
Hagop Kantarjian, MD, interviews Nicholas Short, MD, on treatment sequencing in precursor B-cell ALL and in the relapsed or refractory setting.
In this interview from the Thirteenth annual meeting of the Society of Hematologic Oncology (SOHO 2025), Hagop Kantarjian, MD, hosts Nicholas Short, MD,
The combination of enasidenib, a mutant IDH2 inhibitor, plus venetoclax is safe and shows preliminary activity in patients with relapsed or refractory IDH2-mutated
Updated results from an early-phase chronic lymphocytic leukemia trial of heavily pretreated patients showed that once-daily dosing of the Bruton’s tyrosine kinase (BTK)
A retrospective study of North American children and adolescents published in the New England Journal of Medicine suggests an association between exposure to
A new Biologics License Application (BLA) has been submitted to the US Food and Drug Administration (FDA) for approval of the investigational therapy
The trial, which investigated the efficacy and safety of frontline subcutaneous mosunetuzumab, a CD20/CD30-directed bispecific antibody, was part of the MorningSun basket trial.
Bev Lewyn was 48 years old when her life was upended by two blows in quick succession. In 2015 she was diagnosed with
Anthony G. Letai, MD, PhD, was sworn in on September 29, 2025, as director of the National Cancer Institute (NCI), part of the
The US Food and Drug Administration (FDA) has granted a De Novo Classification Request for the CytoCell KMT2A Breakapart FISH Probe Kit PDx,